Which Exercise Best Lowers Ambulatory BP? - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Which Exercise Best Lowers Ambulatory BP?

‘Combined training and high-intensity interval training were also associated with reductions in 24-hour ambulatory blood pressure’

  • By

  • Kathryn Wighton

  • June 15, 2026

  • 5 min

Share

Objective:

To evaluate the effects of various exercise modalities on 24-hour ambulatory blood pressure in adults with hypertension.

Approach:
    Key Findings:
    • Combined training and high-intensity interval training were associated with a 6-mmHg reduction in 24-hour systolic blood pressure.
    • Aerobic training was associated with a 5-mmHg reduction in 24-hour systolic blood pressure.
    • High-intensity interval training was associated with a 5-mmHg reduction in 24-hour diastolic blood pressure.
    • No exercise modality demonstrated clear superiority over another for reducing blood pressure.
    Interpretation:

    Limitations:
    • Treatment rankings should not be interpreted as definitive evidence of clinical superiority.
    • All comparisons for 24-hour systolic blood pressure were rated as very low confidence.
    • Antihypertensive medication use was incompletely reported in several trials.
    • Adverse events and adherence were underreported.
    • Adults younger than 40 years and older than 75 years were underrepresented.
    Conclusion:

    Sources:

Original Source(s)

Which Exercise Best Lowers Ambulatory BP?

  • by Kathryn Wighton

  • June 15, 2026

Related Content

FDA Approves New Iohexol Vials

The approval includes additional 300 mg iodine/mL and 350 mg iodine/mL vial presentations.

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.